Pharmacokinetics of Depside Salts From Salvia miltiorrhiza in Healthy Chinese Volunteers: A Randomized, Open-Label, Single-Dose Study

被引:24
作者
Jia, Jing-Ying [2 ]
Lu, You-Li [1 ]
Li, Xiao-Chuan [1 ]
Liu, Gang-Yi [2 ]
Li, Shui-Jun [1 ,2 ]
Liu, Yun [2 ]
Liu, Yan-Mei [2 ]
Yu, Chen [2 ]
Wang, Yi-Ping [1 ]
机构
[1] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
[2] Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai, Peoples R China
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 2010年 / 71卷 / 04期
关键词
lithospermic acid B; rosmarinic acid; lithospermic acid; pharmacokinetics; healthy volunteers; liquid chromatography tandem mass spectrometry; LC-MS/MS; MAGNESIUM LITHOSPERMATE-B; ACID; RATS;
D O I
10.1016/j.curtheres.2010.08.004
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND: Depside salts from Salvia miltiorrhiza, with active components of lithospermic acid B (LSB), rosmarinic acid (RA), and lithospermic acid (LA), are a multicomponent drug marketed in China for the treatment of coronary heart disease. OBJECTIVES: The aims of this study were to determine the concentrations of LSB, RA, and LA in human plasma and urine, and to compare the pharmacokinetic properties of depside salts from S miltiorrhiza in healthy Chinese volunteers. METHODS: A randomized, open-label, single-dose study was conducted in healthy Chinese volunteers. Participants were randomly assigned to receive a single intravenous infusion of 100 or 200 mg of depside salts from S miltiorrhiza. Blood was collected through a venous cannula prior to study drug administration (0 min) and at 10, 20, 30, 60, 65, 70, 80, and 90 minutes and 2, 3, 4, 6, 8, 12, and 24 hours after study drug administration. Urine samples were taken before study drug administration (0) and at 0 to 12 and 12 to 24 hours after study drug administration. LSB, RA, and LA concentrations in serum and urine were analyzed by an LC-MS/MS method. Tolerability was determined by clinical assessment; vital signs (ie, blood pressure, heart rate, breathing rate, body temperature) monitoring at baseline and at the end of the study, clinical laboratory tests (ie, hematology, blood biochemistry, hepatic function, renal function, urinalysis), 12-lead ECG measurements, and physical examinations at baseline and after completion of the study. RESULTS: Twelve Chinese volunteers (6 males, 6 females; mean [SD] age, 25.2 [3.8] years; mean height, 165.7 [8.9] cm; mean body mass index, 21.6 [2.5] kg/m(2)) were enrolled in the study. Peak plasma concentrations of LSB, RA and LA were observed at 0.3 to 1 hour following the 1-hour intravenous infusion, with respective mean (SD) C-max of 4925 (1861), 174 (61), and 361 (101) ng/mL for the 100-mg dose and 10,285 (2259), 308 (77), and 674 (85) ng/mL for the 200-mg dose. The AUC(last) values for LSB, RA, and LA were 4537 (1265), 129 (28), and 1229 (330) ng/mL/h, respectively, for the 100-mg dose and 10,426 (2589), 260 (53), and 2792 (729) ng/mL/h for the 200-mg dose. No significant difference in pharmacokinetic parameters was observed between male and female subjects. Three metabolites were found in the plasma with low concentrations. The urinary excretion recoveries of LSB, RA, and LA were 0.58% (0.42%), 25.21% (20.61%), and 10.02% (7.72%) for the 100-mg dose and 0.38% (0.18%), 20.11% (10.50%), and 6.34% (3.20%) for the 200-mg dose. No adverse events were reported by the subjects or found by the investigators in the analysis of vital signs, 12-lead ECG measurements, physical examinations, or clinical laboratory tests. CONCLUSIONS: Following single intravenous infusion of 100 or 200 mg of depside salts from S miltiorrhiza to healthy Chinese subjects, no statistical differences in pharmacokinetic parameters were observed between males and females. The 2 doses of depside salts from S miltiorrhiza were clinically well tolerated during the study. (Curr Ther Res Clin Exp. 2010;71:260-271) (C) 2010 Excerpta Medica Inc.
引用
收藏
页码:260 / 271
页数:12
相关论文
共 17 条
  • [1] Inhibitory effects of lithospermic acid on proliferation and migration of rat vascular smooth muscle cells
    Chen, Li
    Wang, Wen-yi
    Wang, Yi-ping
    [J]. ACTA PHARMACOLOGICA SINICA, 2009, 30 (09) : 1245 - 1252
  • [2] DEMONSTRATION OF THE MYOCARDIAL SALVAGE EFFECT OF LITHOSPERMIC ACID-B ISOLATED FROM THE AQUEOUS EXTRACT OF SALVIA-MILTIORRHIZA
    FUNG, KP
    ZENG, LH
    WU, J
    WONG, HNC
    LEE, CM
    HON, PM
    CHANG, HM
    WU, TW
    [J]. LIFE SCIENCES, 1993, 52 (22) : PL239 - PL244
  • [3] Preventive effect of lithospermate B from Salvia miltiorhiza on experimental hepatitis induced by carbon tetrachloride or D-galactosamine/lipopolysaccharide
    Hase, K
    Kasimu, R
    Basnet, P
    Kadota, S
    Namba, T
    [J]. PLANTA MEDICA, 1997, 63 (01) : 22 - 26
  • [4] Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats
    Kang, DG
    Oh, H
    Sohn, EJ
    Hur, TY
    Lee, KC
    Kim, KJ
    Kim, TY
    Lee, HS
    [J]. LIFE SCIENCES, 2004, 75 (15) : 1801 - 1816
  • [5] Biologically active components from traditional Chinese medicines
    Li, LN
    [J]. PURE AND APPLIED CHEMISTRY, 1998, 70 (03) : 547 - 554
  • [6] Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry
    Li, XC
    Yu, C
    Sun, WK
    Liu, GY
    Jia, JY
    Wang, YP
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2004, 18 (23) : 2878 - 2882
  • [7] Depside salts from Salvia miltiorrhiza improve myocardial microperfusion in rats using laser Doppler flowmetry
    Li, Xiao-fen
    Wang, Yi-ping
    [J]. ACTA PHARMACOLOGICA SINICA, 2007, 28 (06) : 789 - 795
  • [8] Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats
    Li, Xiaochuan
    Yu, Chen
    Lu, Youli
    Gu, Yunlong
    Lu, Jie
    Xu, Wei
    Xuan, Lijiang
    Wang, Yiping
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (02) : 234 - 239
  • [9] MIAO Y, 2006, CLIN PHARM, V17, P140
  • [10] PARNHAM M J, 1985, Drugs of the Future, V10, P756